Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on the stock and has a $60.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc. Sponsored ADR. The company is nearing a critical juncture with the upcoming release of topline data from their ACCESS and ACCESS II studies. The expectation is that their drug, aleniglipron, will demonstrate a 10-12% placebo-adjusted weight loss at clinically relevant doses, while maintaining a favorable tolerability profile with nausea rates below 25% and discontinuation rates under 5%. This outcome would not only validate aleniglipron as a Phase 3 candidate but also make it a strong contender in the acquisition race, especially when considering the emerging oral amylin pipeline.
In addition, the recent acquisition of Metsera by Pfizer underscores the pharmaceutical industry’s interest in differentiated obesity treatments. If Structure’s results exceed expectations, showing weight loss closer to that of injectable treatments or even better tolerability, aleniglipron could transition from a development-stage asset to a strategic acquisition target. This potential for significant upside, coupled with the company’s strategic positioning and ongoing supplementary studies, supports Ghosh’s optimistic outlook and Buy rating for the stock.
In another report released on November 7, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.